Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

B2B sales

- PMLiVE

CureVac expands COVID-19 vaccine trial protocol to include variant specification

Company is aiming to ensure its vaccine efficacy data is 'meaningful' against new virus variants

- PMLiVE

Roche, Regeneron’s COVID-19 antibody cocktail cuts hospitalisation or death by 70%

Phase 3 trial is evaluating the therapy in high-risk non-hospitalised patients with COVID-19

- PMLiVE

Positive late-stage results for Novartis’ radioligand therapy in advanced prostate cancer

Therapy hit both primary endpoints of overall survival and radiographic progression-free survival

- PMLiVE

A lonely planet

The impact of social isolation and loneliness due to COVID-19 has not yet fully revealed itself

- PMLiVE

EU-UK COVID-19 vaccine row continues as export ban discussion looms

EU officials are set to discuss imposing a vaccine export ban this week

Roche Basel Switzerland

Roche’s Tecentriq yields positive data in early stage NSCLC

PD-L1 inhibitor improved disease-free survival in phase 3 IMpower010 study

- PMLiVE

AZ/Oxford COVID-19 vaccine hits primary efficacy endpoint in US-based trial

Specific review of thrombotic events found no increased risk of thrombosis associated with vaccine

- PMLiVE

Setting up for success in a post-Brexit, post-pandemic Britain

Creating a new biotech affiliate and seeking marketing authorisation for a new drug in the UK during a pandemic

- PMLiVE

J&J’s MS drug ponesimod receives approval in the US

US regulator has approved the drug – now named Ponvory – for relapsing forms of MS

- PMLiVE

FDA accepts BMS’ investigational cardiovascular drug mavacamten for review

BMS gained the rights to mavacamten as part of its acquisition of MyoKardia

- PMLiVE

Gilead and Novo Nordisk boost NASH partnership with new mid-stage study

The two companies first announced their NASH collaboration in 2019

- PMLiVE

EMA review confirms AZ/Oxford’s COVID-19 vaccine is safe and effective

EU regulator said that the vaccine is not associated with an increase in the overall risk of blood clots

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links